Ear injection aims to repair Diabetes-Linked hearing damage
NCT ID NCT07472907
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a single injection of CIL001 (Paliroden) into the ear to repair nerve damage that causes hearing problems in people with type 2 diabetes. The trial includes 135 adults aged 45-75 with diabetes for at least 5 years. Researchers will check safety and whether the injection improves the ability to hear speech in noisy settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CIL001 (Paliroden)
- What this could lead to
- If it works, this could point toward a treatment for hearing loss caused by diabetes, and possibly help delay dementia.
- What could go wrong
- This is an early-phase trial with only 135 people, so results may not apply widely. The injection is new and safety is still being checked.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COCHLEAR SYNAPTOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?